Efforts aimed to identify novel molecular players cooperating with KITgain-of-function mutations in the pathogenesis of SM have recently led us to the discovery of a SETD2 protein deficiency in the MCL-like human MC lines HMC-1 and patients with SM. This evidence concerns the gene SETD2 and systemic mastocytosis.